EA201171068A1 - Улучшенные связывающие сывороточный альбумин варианты - Google Patents

Улучшенные связывающие сывороточный альбумин варианты

Info

Publication number
EA201171068A1
EA201171068A1 EA201171068A EA201171068A EA201171068A1 EA 201171068 A1 EA201171068 A1 EA 201171068A1 EA 201171068 A EA201171068 A EA 201171068A EA 201171068 A EA201171068 A EA 201171068A EA 201171068 A1 EA201171068 A1 EA 201171068A1
Authority
EA
Eurasian Patent Office
Prior art keywords
serum albumin
improved connecting
albumin variants
variants
improved
Prior art date
Application number
EA201171068A
Other languages
English (en)
Other versions
EA028178B1 (ru
Inventor
Елена Де Анджелис
Кэролин Эневер
Хайцюнь Лю
Кристофер Пламмер
Оливер Шон
Original Assignee
Глэксо Груп Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глэксо Груп Лимитед filed Critical Глэксо Груп Лимитед
Publication of EA201171068A1 publication Critical patent/EA201171068A1/ru
Publication of EA028178B1 publication Critical patent/EA028178B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Abstract

Изобретение относится к улучшенным вариантам единичного вариабельного домена иммуноглобулина DOM7h-ll, а также к лигандам и конъюгатам лекарственных средств, содержащим такие варианты, к композициям, нуклеиновым кислотам, векторам и хозяевам.
EA201171068A 2009-02-19 2010-02-17 Улучшенные связывающие сывороточный альбумин варианты EA028178B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US15374609P 2009-02-19 2009-02-19
US16398709P 2009-03-27 2009-03-27
US24713609P 2009-09-30 2009-09-30
PCT/EP2010/052008 WO2010094723A2 (en) 2009-02-19 2010-02-17 Improved anti-serum albumin binding variants

Publications (2)

Publication Number Publication Date
EA201171068A1 true EA201171068A1 (ru) 2012-02-28
EA028178B1 EA028178B1 (ru) 2017-10-31

Family

ID=42634270

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201171068A EA028178B1 (ru) 2009-02-19 2010-02-17 Улучшенные связывающие сывороточный альбумин варианты

Country Status (25)

Country Link
US (3) US9534043B2 (ru)
EP (3) EP3656788A3 (ru)
JP (2) JP5759391B2 (ru)
KR (1) KR101819754B1 (ru)
CN (1) CN102405233B (ru)
AR (1) AR075505A1 (ru)
AU (1) AU2010215482B2 (ru)
BR (1) BRPI1013341B1 (ru)
CA (2) CA3079184A1 (ru)
CL (1) CL2011002025A1 (ru)
CO (1) CO6410311A2 (ru)
DO (1) DOP2011000266A (ru)
EA (1) EA028178B1 (ru)
ES (2) ES2774192T3 (ru)
HK (1) HK1247944A1 (ru)
IL (1) IL214480A0 (ru)
MA (1) MA33051B1 (ru)
MX (1) MX2011008749A (ru)
NZ (1) NZ595242A (ru)
PE (1) PE20120001A1 (ru)
SG (1) SG173489A1 (ru)
TW (1) TW201042039A (ru)
UY (1) UY32450A (ru)
WO (1) WO2010094723A2 (ru)
ZA (1) ZA201105657B (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012521971A (ja) * 2009-03-27 2012-09-20 グラクソ グループ リミテッド 薬物融合体および複合体
WO2011008814A2 (en) 2009-07-14 2011-01-20 Immune Tolerance Institute, Inc., A California Not-For-Profit Corporation Multiplexed measurement of exogenous and endogenous dna
SG10201406063XA (en) * 2009-09-30 2014-11-27 Glaxo Group Ltd Drug fusions and conjugates with extended half life
SG10201500274TA (en) * 2009-10-27 2015-03-30 Glaxo Group Ltd Stable anti-tnfr1 polypeptides, antibody variable domains & antagonists
BR112012029280A2 (pt) * 2010-05-20 2016-11-29 Glaxo Group Ltd variante de domínio variável único de imunoglobulina antialbumina sérica, imunoglobulina anti-sa, ligando multiespecífico, proteína de fusão, composição, ácido nucleico, vetor, célula hospedeira isolada, e, uso de uma variante, ligando multiespecífico ou proteína de fusão
JP2013538566A (ja) * 2010-08-13 2013-10-17 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 改良された抗血清アルブミン結合変異体
WO2012069557A1 (en) * 2010-11-24 2012-05-31 Glaxo Group Limited Multispecific antigen binding proteins targeting hgf
EP2646467A2 (en) 2010-12-01 2013-10-09 Glaxo Group Limited Improved anti-serum albumin binding single variable domains
EP2670778A1 (en) 2011-02-02 2013-12-11 Glaxo Group Limited Novel antigen binding proteins
JP7088911B2 (ja) 2016-05-18 2022-06-21 モデルナティエックス インコーポレイテッド リラキシンをコードするポリヌクレオチド
MA49249A (fr) 2017-06-05 2021-04-14 Numab Therapeutics AG Nouveaux anticorps anti-hsa
WO2018224439A1 (en) * 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-hsa antibodies

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US20100081792A1 (en) * 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
JP2006512895A (ja) 2002-06-28 2006-04-20 ドマンティス リミテッド リガンド
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
SI1737962T1 (sl) 2004-03-24 2011-01-31 Domantis Ltd Univerzalni signalni peptid GAS1
BRPI0511755A (pt) 2004-06-01 2008-01-02 Domantis Ltd composições, fusões e conjugados de drogas e métodos de produção, tratamento e utilização
EP1841796A2 (en) 2004-12-02 2007-10-10 Domantis Limited Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
WO2007066109A1 (en) * 2005-12-06 2007-06-14 Domantis Limited Bispecific ligands with binding specificity to cell surface targets and methods of use therefor
EP2441838A3 (en) 2006-01-24 2013-07-10 Domantis Limited Fusion proteins that contain natural junctions
GB0621513D0 (en) 2006-10-30 2006-12-06 Domantis Ltd Novel polypeptides and uses thereof
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
CA2688433A1 (en) * 2007-06-06 2008-12-11 Domantis Limited Methods for selecting protease resistant polypeptides
EP2358754A1 (en) 2008-11-26 2011-08-24 Glaxo Group Limited Ligands that bind il-13
AU2010215479B2 (en) * 2009-02-19 2015-01-22 Glaxo Group Limited Improved anti-TNFR1 polypeptides, antibody variable domains & antagonists
CN102405232B (zh) 2009-02-19 2015-08-19 葛兰素集团有限公司 改良的抗血清清蛋白结合变体
EP2453920A2 (en) * 2009-07-16 2012-05-23 Glaxo Group Limited Antagonists, uses & methods for partially inhibiting tnfr1
SG10201406063XA (en) * 2009-09-30 2014-11-27 Glaxo Group Ltd Drug fusions and conjugates with extended half life
CA2796932A1 (en) * 2010-04-21 2011-10-27 Glaxo Group Limited Binding domains

Also Published As

Publication number Publication date
EP3330287A1 (en) 2018-06-06
EA028178B1 (ru) 2017-10-31
ES2774192T3 (es) 2020-07-17
AR075505A1 (es) 2011-04-06
BRPI1013341B1 (pt) 2021-09-08
EP3656788A2 (en) 2020-05-27
US20110305696A1 (en) 2011-12-15
KR101819754B1 (ko) 2018-01-18
DOP2011000266A (es) 2011-12-31
EP2398826A2 (en) 2011-12-28
US10696738B2 (en) 2020-06-30
CO6410311A2 (es) 2012-03-30
CN102405233B (zh) 2014-11-26
CA2767752A1 (en) 2010-08-26
KR20110127223A (ko) 2011-11-24
US20200283512A1 (en) 2020-09-10
US20170298121A1 (en) 2017-10-19
US9534043B2 (en) 2017-01-03
TW201042039A (en) 2010-12-01
SG173489A1 (en) 2011-09-29
CA3079184A1 (en) 2010-08-26
IL214480A0 (en) 2011-09-27
NZ595242A (en) 2013-11-29
AU2010215482B2 (en) 2014-02-13
PE20120001A1 (es) 2012-02-12
HK1247944A1 (zh) 2018-10-05
ZA201105657B (en) 2012-04-25
CA2767752C (en) 2020-07-07
ES2655071T3 (es) 2018-02-16
MA33051B1 (fr) 2012-02-01
AU2010215482A1 (en) 2011-08-25
WO2010094723A2 (en) 2010-08-26
EP3656788A3 (en) 2020-07-29
MX2011008749A (es) 2011-09-06
JP2012517820A (ja) 2012-08-09
UY32450A (es) 2010-09-30
BRPI1013341A2 (pt) 2016-10-11
CN102405233A (zh) 2012-04-04
EP3330287B1 (en) 2019-12-18
WO2010094723A3 (en) 2011-04-21
CL2011002025A1 (es) 2012-04-09
JP2015204831A (ja) 2015-11-19
JP6100315B2 (ja) 2017-03-22
JP5759391B2 (ja) 2015-08-05
EP2398826B1 (en) 2017-10-25

Similar Documents

Publication Publication Date Title
EA201171067A1 (ru) Улучшенные связывающие сывороточный альбумин варианты
EA201171068A1 (ru) Улучшенные связывающие сывороточный альбумин варианты
EA201270174A1 (ru) Отдельные связывающиеся вариабельные домены с улучшенными свойствами, направленные против сывороточного альбумина
EA201291009A1 (ru) Улучшенные связывающие варианты против сывороточного альбумина
EA201390785A1 (ru) Антитела, обладающие низкой аффинностью к рецепторам гематоэнцефалического барьера, и их применения
EA201490677A1 (ru) Связывающие антиген cd27l белки
CY1119567T1 (el) Θεραπευτικα πεπτιδια
EA201791744A3 (ru) Улучшенная липидная композиция
UA112416C2 (uk) Антитіло до fap і способи його застосування
EA201171494A1 (ru) Миметики белка smac
BR112012025568A2 (pt) proteínas de ligação ao tnf-<244>.
DK2344540T3 (da) Cd86-antagonist multimål bindingsproteiner
WO2011086143A3 (en) Liver targeting domain antibodies
EA201291065A1 (ru) Антитела против vla-4
EA201290642A1 (ru) Соединения и способы
EA201390467A1 (ru) Композиции антител и способы применения
EA201390116A1 (ru) Улучшенные связывающие варианты против сывороточного альбумина
EA201792608A2 (ru) Применение белков p3 бактериофага в качестве агентов, связывающих амилоид
WO2012072731A3 (en) Improved anti-serum albumin binding single variable domains
EA201070484A1 (ru) Новые конъюгаты нейртурина для фармацевтического применения
CR20110473A (es) Variantes de union a anti-albúmina de suero mejoradas.
WO2012136792A3 (en) Cck compositions
CR20110472A (es) Variantes de unión a anti-albumina de suero mejoradas

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU